SCHEMBL8240652

SCHEMBL8240652

C[Si](C)(C)/N=C/c1cccc(Br)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.57
ALDH1A1 P00352 4/20 0.53
LMNA P02545 3/20 0.46
MAPT P10636 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
KDM4E B2RXH2 2/20 0.44
GAA P10253 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
POLB P06746 3/20 0.43
PLEC Q15149 1/20 0.43
CTDSP1 Q9GZU7 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
HSD17B3 P37058 1/20 0.42
CYP1A2 P05177 2/20 0.41
CYP2C19 P33261 2/20 0.41
KMT2A Q03164 3/20 0.41
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22925042 0.78 ALDH1A1 (0.54) NPSR1ALDH1A1LMNAMAPTSMN1; SMN2
SCHEMBL1594957 0.77 ALDH1A1 (0.58) NPSR1ALDH1A1LMNAMAPTNPC1
SCHEMBL1594961 0.77 ALDH1A1 (0.58) NPSR1ALDH1A1LMNAMAPTNPC1
SCHEMBL31668429 0.75 NPC1 (0.44) NPSR1ALDH1A1LMNAMAPTSMN1; SMN2
SCHEMBL3447602 0.74 LMNA (0.52) ALDH1A1LMNAMAPTSMN1; SMN2NPC1
SCHEMBL2488433 0.74 LMNA (0.52) ALDH1A1LMNAMAPTSMN1; SMN2NPC1
SCHEMBL2160777 0.74 ALDH1A1 (0.54) NPSR1ALDH1A1LMNAMAPTSMN1; SMN2
SCHEMBL5110843 0.74 ALDH1A1 (0.54) NPSR1ALDH1A1LMNAMAPTSMN1; SMN2
SCHEMBL2651780 0.74 ALDH1A1 (0.54) NPSR1ALDH1A1LMNAMAPTKDM4E
SCHEMBL20288371 0.74 NPSR1 (0.58) NPSR1ALDH1A1LMNAMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080293709-A1 Novel 2-Amino-Heterocycles Useful in the Treatment of Abeta-Related Pathologies ASTRAZENECA AB (SE) 2008-11-27 US disclosed
US-20080293709-A1 Novel 2-Amino-Heterocycles Useful in the Treatment of Abeta-Related Pathologies ASTRAZENECA AB (SE) 2008-11-27 US disclosed
WO-2007058583-A2 NOVEL 2-AMINO-HETEROCYCLES USEFUL IN THE TREATMENT OF ABETA-RELATED PATHOLOGIES ASTRAZENECA AB (SE) 2007-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293709-A1 Novel 2-Amino-Heterocycles Useful in the Treatment of Abeta-Related Pathologies PSEN2, APP, PSEN1 NPSR1 760/4885ALDH1A1 3152/4885LMNA 1489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.